FDA relabels RebiScan Pediatric Vision Scanner as Class II device

The FDA today said it reclassified RebiScan’s handheld Pediatric Vision Scanner device as a class II device.
RebiScan’s flagship Pediatric Vision Scanner won FDA de novo clearance in June, with indications for screening young children for amblyopia and strabismus.
Boston-based RebiScan put in a request to classify the Pediatric Vision Scanner as a class II device in December, 2013, according to the FDA.
The agency issued an order classifying the device in Class II on June 8, according to the release, and laid out its special controls for the device, which has been labeled under a generic name as a strabismus detection device.
The federal watchdog identified 5 possible risks, including diagnostic risks such as false positives, false negatives and no outputs, electromagnetic interference, electric shock, ocular light toxicity and user error.
To manage diagnostic risks, the FDA said it will require mitigation measures including clinical performance testing, software verification and hazard analysis and appropriate labeling.
Electromagnetic compatibility testing and electrical safety testing were identified as measures to mitigate electromagnetic and electric shock risks. Software verification and validation, hazard analysis and optical radiation safety testing were identified as measures to mitigate ocular light toxicity risks.
The post FDA relabels RebiScan Pediatric Vision Scanner as Class II device appeared first on MassDevice.

Source: Mass Device - September 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance RebiScan Source Type: news